Structure de mise en forme 2 colonnes

PharmaMar

PharmaMar is a biopharmaceutical company determined to advance cancer treatment through discovering, developing, producing, and marketing innovative drugs of marine origin. The company has a unique marine organism library containing over 85,000 specimens. PharmaMar’s R&D has discovered 700 new chemical entities and identified 30 new families of compounds. Yondelis®, developed by PharmaMar, has been approved for the treatment of Soft Tissue Sarcoma, and Relapsed Ovarian Cancer.

Contact


Role/activity of organisation in the project

PharmaMar participate in Nanother providing active anticancer molecules, and evaluating the in vivo activity of the encapsulated molecules into the nanocarriers. The in vivo evaluation of the loaded nanocarriers include toxicological evaluation, pharmacokinetic and antitumoral efficacy in animal models of different implanted tumours .

 

Key people involved in the project

Pilar Calvo, PhD in Pharmaceutical Sciences at the University of Santiago de Compostela, Spain. EXECUTIVE MBA for the Instituto de Empresa of Madrid. In 2001 joined PHARMAMAR as Head of Analytical R&D and Pharmaceutical Development. The main activities are focused on analytical development for molecule characterization and pharmaceutical activities to develop adequate formulations for PharmaMar’s molecules.

Pablo Avilés, PhD in Pharmaceutical Sciences at the Complutense University of Madrid. In 2001 joined PHARMAMAR as Manager of Preclinical Group. The main activities were focused on pharmacokinetic characterisation, preliminary toxicokinetic studies, preliminary metabolism, allometric scaling, and, together clinical pharmacologist, to design phase I and phase II clinical trails.

Carmen Cuevas, PhD in Organic Chemistry at the University of Pais Vasco (Spain). She joined PharmaMar in 1997. In 2003, was promoted to her current position as R&D Director. She has significant experience in discovery, synthesis and development of marine natural products.